Has David Rahimian, DO received payments from drug or device companies?

Yes. Drug and device makers reported $15,353 in general payments to David Rahimian, DO across 675 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Rahimian, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Rahimian, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Rahimian, DO

Neurology · New Hyde Park, NYNPI 1386026060

Payments from drug & device makers

$15,353in general payments, 2019–2025

Across 675 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
AstraZeneca$2K
Pfizer$1K
Neurocrine Biosciences, Inc.$1K
SK Life Science, Inc.$977
Lundbeck LLC$765
plus $7K from 52 others

What the payments were for

Food & beverage$15,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	119	$2,687
AstraZeneca(2 entities)	35	$1,504
Pfizer	70	$1,035
Neurocrine Biosciences, Inc.	42	$1,014
SK Life Science, Inc.	50	$977
Lundbeck LLC	44	$765
Amgen(2 entities)	33	$693
Argenx US, Inc.	19	$538
TG Therapeutics, Inc.	10	$482
Takeda Pharmaceuticals U.S.A., Inc.	15	$438
Eisai Inc.	15	$402
Biogen	19	$391
Novartis	26	$308
Chiesi USA, Inc.	12	$260
Merck	11	$221
Cumberland Pharmaceuticals, Inc.	12	$219
Impel Pharmaceuticals Inc.	9	$214
EMD Serono, Inc.	12	$208
Grifols USA, LLC	9	$207
Lilly USA, LLC	10	$193
Amneal Pharmaceuticals LLC	8	$182
Alnylam Pharmaceuticals Inc.	3	$159
Johnson & Johnson(2 entities)	2	$158
Genentech USA, Inc.	5	$151
Penumbra, Inc.	1	$140
Mallinckrodt Hospital Products Inc.	2	$131
Amylyx Pharmaceuticals, Inc.	1	$125
Kyowa Kirin, Inc.	5	$120
Scilex Pharmaceuticals Inc.	5	$113
Acadia Pharmaceuticals Inc	7	$101
Biohaven Pharmaceutical Holding Company Ltd.	4	$96
Teva Pharmaceuticals USA, Inc.	5	$93
Corium, LLC	10	$93
Otsuka America Pharmaceutical, Inc.	4	$91
Merz Pharmaceuticals, LLC	3	$72
CSL Behring	3	$69
Axsome Therapeutics, Inc.	2	$57
MDD US Operations, LLC	3	$52
Catalyst Pharmaceuticals, Inc.	3	$50
Avanir Pharmaceuticals, Inc.	2	$48
Acorda Therapeutics, Inc	3	$44
UCB, Inc.	2	$44
Tanabe Pharma America, Inc.	2	$42
Banner Life Sciences, LLC	2	$39
Ipsen Biopharmaceuticals, Inc	1	$33
Vanda Pharmaceuticals Inc.	2	$32
Octapharma USA, Inc.	2	$30
Boston Scientific	1	$28
Eagle Pharmaceuticals, Inc.	1	$27
Vertex	1	$27
Xeris Pharmaceuticals, Inc.	1	$25
Supernus Pharmaceuticals, Inc.	1	$23
Sanofi	1	$22
Azurity Pharmaceuticals, Inc.	1	$20
Bristol Myers Squibb	1	$17
Neurelis, Inc.	1	$17
Mylan Specialty L.p.	1	$16
GE HealthCare	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,353 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024

$339,872

Medicare patients

1,002

Services billed

2,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl	165	$4,823
Quetiapine Fumarate	63	$2,474
Donepezil Hcl	212	$2,198
Levetiracetam	103	$2,128
Gabapentin	94	$1,136
Lacosamide	14	$529
Carbidopa-LevodopaCarbidopa/Levodopa	27	$456
Sumatriptan Succinate	35	$393
Duloxetine Hcl	25	$291
Atorvastatin Calcium	14	$239
Nortriptyline Hcl	26	$212
ClopidogrelClopidogrel Bisulfate	30	$178
Topiramate	15	$172
Pregabalin	17	$153
Trazodone Hcl	12	$134

Paid to pharmacies, not to this prescriber.

Other neurology in New Hyde Park

Christian GrommesNew York$9.9M
Ilya KisterNew York$9.5M
E DorseyNew York$8.5M
Lauren SchaffNew York$8.2M
Richard HolubAlbany$6.3M
Martin SadowskiNew York$5.4M
Lawrence HonigNew York$4.9M
Laszlo MechtlerAmherst$4.3M
Bennett MyersAmherst$3.8M
Krupa PandeyAlbany$3.8M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →